Mersana Therapeutics在1月5日更新了XMT-1536(UpRi)的临床数据。XMT-1536是靶向NaPi2b的抗体偶联药物(ADC),在1期临床的卵巢癌拓展队列中,ORR数据从去年5月公布的35%下降至28%,安全性上有31%的患者由于治疗引起的不良反应减少剂量、推迟用药或停止治疗,39%的患者发生严重不良事件,发生了1例5级肺炎。截止1月5日...
其他即將推出的數據演示:2024年上半年,Mersana預計將在多個科學會議上展示數據,證明Dolasynthen與第一代細胞毒性ADC平台的區別。演講將包括兩種已停產的ADC候選藥物XMT-1592和XMT-1536(UpRi)的臨床數據。合作:Mersana繼續推進與JanssenBiotech, Inc.和德國達姆施塔特默克公司的合作。與Janssen的合作和許可協議的重點是為多...
2022-RA-459-ESGOUPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancerdoi:10.1136/ijgc-2022-ESGO.511Introduction/Background UpRi is a first-in-class NaPi2b-...
XMT-1536 is a NaPi2b targeting ADC comprised of a unique humanized antibody conjugated with 10-15 auristatin F- hydroxypropylamide (AF-HPA) payload molecules via the Dolaflexin platform. AF-HPA is a cell-permeable, antimitotic compound that is slowly metabolized intratumorally to an active, very...
Upifitamab Rilsodotin(XMT-1536)是一种新型抗体-药物偶联物(ADC),由靶向NaPi2b的IgG抗体与细胞毒性药物AF-HPA通过创新型连接子偶联而成。XMT-1536能够实现肿瘤表面药物浓度的显著提升,同时其有效载荷AF-HPA具备可控的旁观者效应和有限的扩散能力,从而减少对周围健康细胞的杀伤作用。XMT-1536结合了高靶向性与低毒性...
目的探讨质量改进(quality improvement, QI)促进极早产儿实施延迟脐带结扎(delayed cord clamping, DCC)的作用。 方法回顾性收集2017年1月至2021年1月重庆医科大学附属妇女儿童医院出生并转入新生儿科的极早产儿的基本资料和QI评价指标。QI评价指标包括(...
党员干部离职或者退(离)休后,其原有的职权还会在一定范围、一定时期内产生影响或者发挥作用。新修订的《中国共产党纪律处分条例》对离岗离职后违规从业、违规谋利行为列出负面清单,作出处分规定,旨在堵住政商“旋转门”、期权式腐败等漏洞...
The FDA granted an orphan drug designation to XMT-2056, an immunosynthen STING-agonist antibody-drug conjugate (ADC), for the treatment of patients with gastric cancers, according to Mersana Therapeutics.1 XMT-2056 revealed more than 100-fold increased potency compared to the free STING-agonist ...
#168UPLIFT (ENGOT-Ov67/GOG-3048): results from the phase 2 trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate (ADC) in platinum-resistant ovarian cancer (PROC)doi:10.1136/ijgc-2024-ESGO.1118...
Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076)Objectives:Effective and well-tolerated treatments for platinum-resistant ovarian cancer (PROC) remain a substantial ...